Quantcast
Last updated on April 23, 2014 at 21:24 EDT

Latest Angiogenesis inhibitor Stories

2011-01-14 13:53:00

TOORAK, Australia, Jan. 14, 2011 /PRNewswire/ -- Circadian Technologies (ASX.CIR) is very pleased to announce today that its subsidiary company Vegenics Pty Limited, has been granted an exclusive, global licence by Chugai Pharmaceutical Co, Ltd. granting access to Chugai IP relating to VEGF-D. Circadian and Chugai both hold extensive VEGF-D IP portfolios which have overlapped throughout the world. This licence enables Circadian to enhance its intellectual property portfolio and secure...

2010-12-14 08:20:43

(Ivanhoe Newswire) -- Halting the growth of melanoma tumors by targeting the MIC-1 protein that promotes blood vessel development in tumors may lead to improved treatment of this invasive and detrimental cancer. "Preventing vessels from developing in tumors is one way to stop them from growing," which lead author Gavin Robertson, Ph.D., professor of pharmacology, pathology, dermatology and surgery at Penn State College of Medicine, and researcher in The Foreman Foundation Research Laboratory,...

2010-12-09 19:53:29

A novel strategy of blocking the growth of blood vessels with antibodies should result in improved treatment of cancerous tumors. The growth of new blood vessels from pre-existing vasculature is called angiogenesis. In adults, angiogenesis occurs only during wound healing and menstrual cycling, but is abundant and harmful in cancerous tumors and the old-age eye disease frequently leading to blindness called age-related macular degeneration (AMD). Without the formation of new blood vessels,...

2010-12-09 17:42:26

Halting the growth of melanoma tumors by targeting the MIC-1 protein that promotes blood vessel development in tumors may lead to better treatment of this invasive and deadly cancer, according to Penn State College of Medicine researchers in The Foreman Foundation Research Laboratory. "Preventing vessels from developing in tumors is one way to stop them from growing," said lead author Gavin Robertson, Ph.D., professor of pharmacology, pathology, dermatology and surgery. "However, the identity...

2010-11-19 12:32:49

Phase I trial shows first drug to inhibit ALK-1 receptor is safe and effective Researchers have found that a newly developed drug, which is aimed at a particular receptor involved in the development of blood vessels that sustain tumour growth, is active in patients with advanced cancers and, in some cases, has halted the progress of the disease. The drug, ACE-041, targets a different molecular pathway to other anti-angiogenesis drugs and may provide a new option to treat cancer. Results from...

2010-06-29 08:00:00

WALTHAM, Mass., June 29 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, through 2019, robust 4.1 percent annual growth in the renal cell carcinoma drug market will be driven primarily by the uptake of GlaxoSmithKline's Votrient/Patorma, the launches of premium-priced emerging therapies and an increase in diagnosed incidence and treatment rates. The Pharmacor 2010 findings from the topic...

2010-06-09 17:42:36

A blood vessel-blocking drug called tasquinimod slowed the rate of disease progression in a clinical trial of 200 prostate cancer patients, according to experts at Johns Hopkins, Roswell Park Cancer Institute and Duke University. Tasquinimod is a so-called "anti-angiogenesis" drug that squeezes off blood supply to prostate tumors by blocking new blood vessel development. Tumors require these vast networks of blood vessels to supply nutrients. The multicenter trial at seven institutions,...

2010-03-05 09:47:35

Today, during the 39th Annual Meeting of the American Association for Dental Research, convening at the Walter E. Washington Convention Center in Washington, DC, lead researcher M. Tong, The Ohio State University, will present a poster of a study titled "Epithelial-to-Endothelial Transition: An Epithelial Phenotypic Modulation Facilitating Oral-Squamous-Cell Carcinoma Progression." Tong and a team of researchers have reported that oral squamous cell carcinoma (OSCC) cells endogenously produce...

67264525ec2ff3e26be72929161b75bd1
2010-02-12 06:35:00

Researchers say dark chocolate and red wine may join other foods - such as blueberries, garlic, soy, and tea - as potent medicines in the fight against cancer. The results of the study were presented by the researchers at the renowned TED Conference on Wednesday. "We are rating foods based on their cancer-fighting qualities," William Li, head of the Angiogenesis Foundation, told AFP. "What we eat is really our chemotherapy three times a day." The foundation is studying foods which...

2010-01-11 13:14:45

Researchers at Karolinska Institutet have discovered a new way of blocking the formation of blood vessels and halting the growth of tumors in mice. A substance that exploits this mechanism could be developed into a new treatment for cancer. For a cancer tumor to be able to grow larger than the size of a pea, the cancer cells need to stimulate the formation of new blood vessels that can supply the tumor with oxygen and nutrients, a process known as angiogenesis. A number of medicines which...